Burixafor

DB11970InvestigationalSmall molecule

Burixafor has been used in trials studying the treatment of Multiple Myeloma, Hodgkin's Disease, and Non-hodgkin's Lymphoma.

Mechanism: Pharmacologically active on C-X-C chemokine receptor type 4
Curator reviewed
Formula / weight: C₂₇H₅₁N₈O₃P · 566.732 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyQLVSJMZJSABWRX-YHBQERECSA-NSMILESNC1=NC(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)=NC(=C1)N1CCN(CCP(O)(O)=O)CC1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Burixafor, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.